Purpose Platinum-based regimens represent the typical first-line treatment for non-small-cell lung cancer (nsclc). period (ci): 0.80 to 0.99. The success benefit was limited by sufferers with non-squamous histology: hr: 0.82; 95% ci: 0.73 to 0.91. Pemetrexed was inferior compared to other chemotherapy choices in sufferers with squamous histology: hr: 1.19; 95% ci: 0.99 to at… Continue reading Purpose Platinum-based regimens represent the typical first-line treatment for non-small-cell lung